MedPath

Exposure of NICU Patients to PVC Plasticizers in At-risk Clinical Situation: Biomonitoring Study From Urinary Samples

Conditions
Patient Hospitalized in NICU
Neonates or Premature Babies
Patient With Urinary Catheter
Interventions
Other: plasticizers
Registration Number
NCT03477409
Lead Sponsor
University Hospital, Clermont-Ferrand
Brief Summary

In response to restrictions related to the use of DEHP as a plasticizer for PVC medical devices (MDs), manufacturers have resorted to alternative plasticizers. These are now integrated into many MDs such as infusion sets, extension lines, extracorporeal circuits, nutrition tubings ... etc. The ARMED project (2012-2015) funded by the ANSM, whose goal was to prioritizing the risk linked to the migration of these plasticizers from MDs, has shown that TOTM and DEHT present the best benefit / risk ratio due to lower migration and cytotoxicity. Nevertheless, it is important to evaluate the level of exposure of neonatal intensive care patients, due to the multi exposure to MD made of PVC, the frequent use of intravenous route and the vulnerability of this at-risk population to the metabolites of these plasticizers.

Detailed Description

The purpose of this biomonitoring study consists to evaluate the exposure of newborns and premature babies hospitalized in NICU to these plasticizers (DEHT and TOTM), by qualitative and quantitative measurement of their urinary metabolites

Recruitment & Eligibility

Status
UNKNOWN
Sex
All
Target Recruitment
90
Inclusion Criteria
  • hospitalized minor patient in NICU
  • hospitalized patient in one of the planned services of the study- hospital stay provided for inclusion ≥ 48 hours
  • patient with a urinary catheter at the time of inclusion in the study
  • patient undergoing during the stay at least 1 of the following medical procedures: enteral nutrition, parenteral nutrition, extra-renal purification, ECMO, transfusion, lipid infusion, plasmapheresis
  • patient whose parents have expressed their non-opposition to his participation in the study
Exclusion Criteria
  • death of the patient
  • leaving hospital
  • patient becoming anuric (diuresis <1mL / kg / h for more than 24 hours) under study

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Arm && Interventions
GroupInterventionDescription
Neonatal intensive care patientsplasticizersThe purpose of this biomonitoring study consists to evaluate the exposure of newborns and premature babies hospitalized in NICU to these plasticizers (DEHT and TOTM), by qualitative and quantitative measurement of their urinary metabolites
Primary Outcome Measures
NameTimeMethod
Measurement of urinary levels of DEHT metabolitesat day 1

The studied metabolites are specific biological markers

Measurement of urinary levels of TOTM metabolitesat day 1

The studied metabolites are specific biological markers

Secondary Outcome Measures
NameTimeMethod
Correlation of urinary levels of TOTM and DEHT metabolites to corresponding plasticizers doses released by PVC medical devices to which patients are exposed18 months after the beginning of the study

Quantities of plasticizers (TOTM and DEHT) are measured within each MD to which neonates are exposed in NICU. The release doses of plasticizers are evaluated with mathematical model (built from ex vivo experimentations). The study evaluates whether there is a correlation between the doses of TOTM and the DEHT released by the MD and the metabolites levels found in the urine of exposed patients

Comparison of urinary levels of TOTM and DEHT and their metabolites to in vitro cytotoxicity and endocrine disruption and to toxicological data from the literature.18 months after the beginning of the study

The Armed Neo project include laboratory studies to evaluate the cytotoxicity and endocrine disrupting effects of plasticizers and their metabolites. These studies show the concentrations above which DHT, TOTM and metabolites are toxic. The concentrations obtained in the urines of newborns will be compared to these toxicity threshold values

Trial Locations

Locations (1)

CHU Clermont-Ferrand

🇫🇷

Clermont-Ferrand, France

© Copyright 2025. All Rights Reserved by MedPath